Thermo Fisher Announces $3.5 Billion Acquisition of Phadia

Thermo Fisher Announces $3.5 Billion Acquisition of Phadia

Attorney News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Globally connected lawyers counseling clients on complex business and policy matters.
Globally connected lawyers counseling clients on complex business and policy matters.
Focusing on international arbitration and dispute resolution, investigations, financial services enforcement, and IP litigation.
Germany

Longtime WilmerHale client Thermo Fisher Scientific Inc. announced that it has signed a definitive agreement to acquire Phadia-a Sweden-based company that develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases-from European private equity firm Cinven. The deal is valued at approximately $3.5 billion in cash and is expected to be completed in the fourth quarter of 2011. Thermo Fisher, a Waltham, Massachusetts-based company, will incorporate Phadia as part of its Specialty Diagnostics business within its Analytical Technologies Segment.

Partner Hal Leibowitz, chair of WilmerHale's Corporate Group, led the team advising Thermo Fisher on the acquisition. Other members of the WilmerHale team included Partners Christian Crones, Jeffrey A. Hermanson, Tim Matthews, Lester Ross, Sven Volcker and Kenneth Zhou; Counsel Cormac O'Daly, Jerry Marr and David Morris; Senior Associates Lisa Arsenidou, Elizabeth Black, Suzy Byron, Stefan Eggert, Aileen Gao and Alison Kapilow; and Associates Philippe Claessens, Christina Frangos, Franziska Irmer, Frederik Rother and Franziska von Kummer. A press release explaining this transaction in greater detail is available on Thermo Fisher's website.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel